Yuan-Hong Huang

Yuan-Hong Huang

Auto-generated profile, based on publicly available information

Yuan-Hong Huang

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
YLYan-Yan Li
Yan-Yan Li
SGShuai-Shuai Ge
Shuai-Shuai Ge
YHYuan-Hong Huang
Yuan-Hong Huang
MXMing-Zhu Xu
Ming-Zhu Xu
CWChao-Ling Wan
Chao-Ling Wan
HDHaiping Dai
Haiping Dai

6 October 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
YHYuan-Hong Huang
Yuan-Hong Huang
FLFang-Tong Liu
Fang-Tong Liu
CWChao-Ling Wan
Chao-Ling Wan
ZWZi-Jin Wang
Zi-Jin Wang
YLYu-Qing Liu
Yu-Qing Liu
SXSheng-Li Xue
Sheng-Li Xue
Acute myeloid leukemia with myelodysplasia-related changes (AML-MR), a high-risk subtype affecting older patients intolerant to intensive chemotherapy. Venetoclax-based regimens are approved for such patients, while studies suggest priming regimens combining aclarubicin, homoharringtonine or idarubicin and low-dose cytarabine with granulocyte colony-stimulating factor may replace intensive therapy, while direct comparisons are lacking in two groups. This retrospective study compared venetoclax plus hypomethylating agents (VEN+HMA) and priming regimens in 150 propensity score-matched AML-MR patients. VEN+HMA demonstrated superior overall remission (ORR: 78.7% vs. 60.0%, p = 0.013) and complete remission (CR: 48.0% vs. 21.3%, p < 0.001) rates. Notably, VEN+HMA significantly improved median overall survival (OS: not reached vs. 36.37 months, p = 0.026) and event-free survival (EFS: not reached vs. 7.37 months, p = 0.003). Multivariate analysis confirmed VEN+HMA as an independent predictor of better ORR (OR = 2.855, p = 0.014), OS (HR = 0.449, p = 0.036), and EFS (HR = 0.458, p = 0.003). These findings suggest VEN+HMA may be a preferable low-intensity induction therapy over priming regimens for AML-MR.